Mechanisms underlying skin disorders induced by EGFR inhibitors

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in cancer therapy, with inhibitors widely used for various tumors.
• While EGFR inhibitors offer therapeutic benefits, they frequently cause cutaneous side effects, impacting treatment adherence and efficacy.
• The precise mechanisms of these skin toxicities and their correlation with treatment effectiveness are not fully understood.

Purpose of the Study:

• To review the molecular and cellular mechanisms behind EGFR inhibitor-induced skin toxicities.
• To explore potential adjuvant therapeutic strategies to mitigate these side effects.
• To identify optimal targets for alleviating cutaneous toxicities associated with EGFR inhibition.

Main Methods:

• Comprehensive literature review of studies on EGFR inhibitors and their cutaneous side effects.
• Analysis of molecular and cellular pathways involved in EGFR signaling in skin.
• Evaluation of evidence supporting keratinocytes as therapeutic targets.

Main Results:

• EGFR inhibitors, while effective against cancers like carcinomas and glioblastoma, induce dose-limiting skin toxicities.
• The correlation between side effect intensity and therapeutic efficacy suggests a complex biological interplay.
• Current literature suggests keratinocytes play a crucial role in mediating these adverse skin reactions.

Conclusions:

• Understanding the mechanisms of EGFR inhibitor-induced skin toxicity is crucial for optimizing cancer treatment.
• Targeting keratinocytes presents a promising strategy for developing adjuvant therapies to manage skin side effects.
• Alleviating skin toxicities can improve patient quality of life and maintain the effectiveness of anti-EGFR therapy.